IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Buys 50,000 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 50,000 shares of the stock in a transaction on Monday, May 12th. The stock was purchased at an average price of $1.16 per share, for a total transaction of $58,000.00. Following the completion of the purchase, the insider owned 248,348 shares of the company’s stock, valued at approximately $288,083.68. This trade represents a 25.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

IRIDEX Stock Performance

IRIX stock opened at $0.88 on Thursday. The company has a market capitalization of $15.46 million, a price-to-earnings ratio of -4.40 and a beta of 0.67. IRIDEX Corporation has a fifty-two week low of $0.61 and a fifty-two week high of $1.65. The stock has a fifty day moving average of $0.73 and a 200-day moving average of $0.95.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. Equities analysts predict that IRIDEX Corporation will post -0.12 EPS for the current year.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, IRIDEX has an average rating of “Hold” and a consensus price target of $3.00.

Hedge Funds Weigh In On IRIDEX

Several hedge funds have recently made changes to their positions in IRIX. Bank of New York Mellon Corp bought a new stake in shares of IRIDEX during the 2nd quarter valued at $29,000. Diversify Advisory Services LLC purchased a new stake in IRIDEX during the 2nd quarter worth about $30,000. Diversify Wealth Management LLC purchased a new stake in IRIDEX during the 1st quarter worth about $35,000. United Capital Financial Advisors LLC bought a new position in IRIDEX in the 2nd quarter worth about $41,000. Finally, Thompson Davis & CO. Inc. boosted its stake in IRIDEX by 66.5% in the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 18,944 shares during the period. 20.10% of the stock is currently owned by hedge funds and other institutional investors.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.